A new take on growth factor signalling in tamoxifen resistance

Differences in growth factor (GF) signalling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some oestrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signalling...

Read the whole article on

More from